Bluesky Facebook Reddit Email

Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness

01.28.25 | Terasaki Institute for Biomedical Innovation

CalDigit TS4 Thunderbolt 4 Dock

CalDigit TS4 Thunderbolt 4 Dock simplifies serious desks with 18 ports for high-speed storage, monitors, and instruments across Mac and PC setups.


Los Angeles, CA – January 28, 2025 - Researchers at the Terasaki Institute for Biomedical Innovation have developed an innovative delivery system that could significantly improve the effectiveness of peptide-based cancer vaccines, according to a new study published in Advanced Functional Materials . The breakthrough centers on a new class of materials called lipopeptide hydrogels (LPHs), which show promise in boosting immune responses and possess adjuvant-like properties.

"Traditional peptide-based cancer vaccines, while safer than many alternatives, often struggle to provoke a strong enough immune response," explains Dr. Natashya Falcone, the study's lead investigator. "Our findings demonstrate that these novel LPHs could overcome this limitation by serving both as a depot delivery system and an adjuvant to boost the immune response. This dual-action approach could be transformative for cancer vaccine development."

The research team engineered these hydrogels to deliver a specific peptide that targets hepatocellular carcinoma (HCC), the most common type of primary liver cancer. The LPH system demonstrated sustained release of the cancer-targeting peptide over a two-week period, enhanced uptake by immune cells, activated immune cells called antigen-presenting cells by increasing co-stimulatory molecule expression, and increased immune cell presence in lymph nodes without observable toxic effects in vivo.

"This innovative research exemplifies our commitment to developing breakthrough technologies that can revolutionize vaccine treatment," says Dr. Ali Khademhosseini, CEO of the Terasaki Institute for Biomedical Innovation. "The potential impact of this adjuvant-like delivery system extends beyond liver cancer, potentially opening new avenues for more effective cancer vaccines across multiple types of tumors.”

For more information, contact:

Dr. Natashya Falcone

Terasaki Institute for Biomedical Innovation

Email: nfalcone@terasaki.org

The Terasaki Institute for Biomedical Innovation is a non-profit organization dedicated to advancing biomedical research and innovation. With a focus on developing technologies that improve human health, the institute collaborates with leading researchers and institutions worldwide.

###

Advanced Functional Materials

10.1002/adfm.202413870

Experimental study

Lab-produced tissue samples

Lipopeptide Hydrogel Possesses Adjuvant-Like Properties for the Delivery of the GPC-3 Peptide-derived Antigen

24-Jan-2025

Keywords

Article Information

Contact Information

Stewart Han
Terasaki Institute for Biomedical Innovation
shan@terasaki.org

Source

How to Cite This Article

APA:
Terasaki Institute for Biomedical Innovation. (2025, January 28). Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness. Brightsurf News. https://www.brightsurf.com/news/86Z2W398/scientists-develop-novel-adjuvant-delivery-system-to-enhance-cancer-vaccine-effectiveness.html
MLA:
"Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness." Brightsurf News, Jan. 28 2025, https://www.brightsurf.com/news/86Z2W398/scientists-develop-novel-adjuvant-delivery-system-to-enhance-cancer-vaccine-effectiveness.html.